Pharming Group (PHARM.AS) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
You don't hold PHARM.AS in your mock portfolio yet.
The very high PE ratio relative to minimal EPS suggests the stock price is rich versus current earnings power. With EPS at just €0.01, profitability appears thin, implying that much of the valuation rests on future growth expectations rather than demonstrated financial strength. Without evidence of strong revenue or margin expansion, the risk/reward skews unfavorably at current earnings levels.
The stock trading at €0.99, well below its 200-day moving average of €1.32, points to a sustained downtrend. A 13.9% decline over the last month reinforces negative momentum and suggests weak near-term sentiment. Without a clear reversal signal, the technical setup leans to the downside.
Alternative data are mixed and relatively muted in scale. Modest growth in job openings suggests some operational or growth investment, but digital presence and social media traction remain very small and are growing only marginally. Overall, these signals neither strongly confirm nor contradict the bearish picture from valuation and price action.
Overall, Pharming Group’s setup appears bearish: the stock trades in a clear downtrend while carrying a high earnings multiple on very modest profitability. Alternative data show only slight signs of expansion and do not provide a strong counterweight to valuation and technical concerns. Unless earnings growth accelerates meaningfully or technicals improve, the risk profile looks skewed to the downside.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started